Table 1.
Participants’ characteristics/results of lung function and exercise testing
| Patients with CF (n = 20) | Healthy controls (n = 23) | |
|---|---|---|
| Female (n/[%]) | 6 [30] | 10 [43] |
| Anthropometric data | ||
| Age (years) | 21.7 ± 8 (12–42) | 21.2 ± 6 (15–43) |
| Height (cm) | 164.4 ± 12.0 (138–185) | 174.5 ± 7.5 (160–192) *** |
| Weight (kg) | 56.6 ± 13.9 (31–79) | 67.8 ± 8.7 (52–94) *** |
| Lung function | ||
| FEV1 (%pred) | 74.3 ± 20.4 (25.7–103.0) | 103.3 ± 12.2 (77.2–123.6) *** |
| FVC (%pred) | 91.2 ± 17.0 (41.4–96.4) | 101.0 ± 10.3 (77.2–125-8) * |
| RV%TLC | 30.7 ± 13 (23.7–41.8) | 22.9 ± 4 * (19.3–31.3) |
| TLCO% | 86.7 ± 17.4 (47.8–112.5) | 94.4 ± 17.6 (67.8–128.0) |
| Incremental cycling exercise test (Godfrey protocol) | ||
| VO2 peak (%pred) | 77.8 ± 16.2 (44.3–110.1) | 100.6 ± 18.8 (60.1–136-0) *** |
| VO2peak/qCSA ml/min | 36.5 ± 7.4 (23.4–53.1) | 49.1 ± 11.4 (23.5–77.7) *** |
| RER | 1.17 ± 0.1 (0.9–1.4) | 1.21 ± 0.1 (1.1–1.4) |
| Peak heart rate (bpm) | 171 ± 15.4 (140–201) | 183 ± 9.8 (166–202) ** |
| SPO2 peak exercise (%) | 96 ± 2.6 (90–100) | 98 ± 2.1 (91–100) * |
All parameters are reported as mean ± standard deviation (range); differences between participants with and without CF were calculated using Student’s t-test. Significant data is marked by ***p < 0.001, ** p < 0.01, * p < 0.05